Access to life-saving medicines such as insulin is a basic human right. However, the high price of insulin is a serious problem for millions of people around the world.

DeSci ( *decentralized science ) represents a new paradigm that can facilitate the development of cheaper insulin analogues.

___

*Before reading this article, I advise you to read the first part:

https://mirror.xyz/obchakevich.eth/U-QCJmcOQQeltJgomnwaI5RDhClB-M7py3MhNAGbqwY

___

DeSci platforms could facilitate open source research on new insulin analogs, potentially bypassing traditional pharmaceutical companies and their profit motives. This could lead to rapid development of cheaper insulin and broader accessibility.

The DeSci projects also has the potential to promote open access to research data, foster collaboration, and accelerate the search for cost-effective solutions.

Situation:

For every $100 spent on retail drugs, $41 go to parties in the distribution chain: wholesalers, pharmacies, pharmacy benefit managers, and insurers.

The growing difference between the list price and the net price of a drug reflects negotiated rebates and discounts put into place to influence formulary placement among competing brands within a drug class.

High list prices disadvantage patients who pay the list price or pay coinsurance based on the list price of the medication and impact both medication adherence and health outcomes. To address these issues, greater transparency and simplicity should be introduced into drug pricing to eliminate distortions that are currently beyond individual payers’ ability to address.

In addition, when only a few manufacturers produce a drug, they may capitalize on their strategic positions to minimize competition and drive up prices. One of these strategies is “shadow pricing” in which the prices of competitor products increase at similar rates around the same time.

DeSci alone cannot directly address issues such as market exclusivity for biosimilar drugs and anti-competitive practices by well-known pharmaceutical companies.

The increasing use of more expensive insulin analogs to replace less expensive human and animal insulins has led to an increase in insulin prices and spending and negatively affected the affordability of insulin for health systems and individuals around the world.

Overall, DeSci promises to contribute to solving the problem of low-cost insulin, but it is important to consider its limitations and the need for additional approaches, such as policy and regulatory changes, to address other aspects of the problem.

This area can be a powerful tool for the development of affordable insulin. With the right approach and stakeholder support, DeSci could change the lives of millions of people with diabetes.

Materials for diving into the topic:

https://mirror.xyz/obchakevich.eth/U-QCJmcOQQeltJgomnwaI5RDhClB-M7py3MhNAGbqwY

https://medicine.yale.edu/news-article/the-price-of-insulin-a-qanda-with-kasia-lipska/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597930/#:~:text=Structural%20Factors,negotiations%20with%20pharmacy%20benefit%20managers

https://www.nbcnews.com/news/amp/rcna39295

Access to life-saving medicines such as insulin is a basic human right. However, the high price of insulin is a serious problem for millions of people around the world.

DeSci ( *decentralized science ) represents a new paradigm that can facilitate the development of cheaper insulin analogues.

___

*Before reading this article, I advise you to read the first part:

https://mirror.xyz/obchakevich.eth/U-QCJmcOQQeltJgomnwaI5RDhClB-M7py3MhNAGbqwY

___

DeSci platforms could facilitate open source research on new insulin analogs, potentially bypassing traditional pharmaceutical companies and their profit motives. This could lead to rapid development of cheaper insulin and broader accessibility.

The DeSci projects also has the potential to promote open access to research data, foster collaboration, and accelerate the search for cost-effective solutions.

Situation:

For every $100 spent on retail drugs, $41 go to parties in the distribution chain: wholesalers, pharmacies, pharmacy benefit managers, and insurers.

The growing difference between the list price and the net price of a drug reflects negotiated rebates and discounts put into place to influence formulary placement among competing brands within a drug class.

High list prices disadvantage patients who pay the list price or pay coinsurance based on the list price of the medication and impact both medication adherence and health outcomes. To address these issues, greater transparency and simplicity should be introduced into drug pricing to eliminate distortions that are currently beyond individual payers’ ability to address.

In addition, when only a few manufacturers produce a drug, they may capitalize on their strategic positions to minimize competition and drive up prices. One of these strategies is “shadow pricing” in which the prices of competitor products increase at similar rates around the same time.

DeSci alone cannot directly address issues such as market exclusivity for biosimilar drugs and anti-competitive practices by well-known pharmaceutical companies.

The increasing use of more expensive insulin analogs to replace less expensive human and animal insulins has led to an increase in insulin prices and spending and negatively affected the affordability of insulin for health systems and individuals around the world.

Overall, DeSci promises to contribute to solving the problem of low-cost insulin, but it is important to consider its limitations and the need for additional approaches, such as policy and regulatory changes, to address other aspects of the problem.

This area can be a powerful tool for the development of affordable insulin. With the right approach and stakeholder support, DeSci could change the lives of millions of people with diabetes.

Materials for diving into the topic:

https://mirror.xyz/obchakevich.eth/U-QCJmcOQQeltJgomnwaI5RDhClB-M7py3MhNAGbqwY

https://medicine.yale.edu/news-article/the-price-of-insulin-a-qanda-with-kasia-lipska/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597930/#:~:text=Structural%20Factors,negotiations%20with%20pharmacy%20benefit%20managers

https://www.nbcnews.com/news/amp/rcna39295